US › Healthcare

Anixa Biosciences Inc (ANIX)

US · Healthcare · Biotechnology

$3.18+4.95%

Last close · 2026-11-06

Latest quarter · ended 2026-07-31

Revenue

Net profit

$-2.6M

EPS

$-0.08

EPS estimate

$-0.08

EPS came in at -0.08 against a street estimate of -0.08 — a beat of 0.0%.

Key statistics

Market cap

$114.0M

Forward P/E

0.0

P/B

7.18

Book value

$0.42

EPS (TTM)

$-0.34

52-week high

$5.46

52-week low

$2.32

50-day MA

$2.95

200-day MA

$2.97

Beta

0.45

Analyst view

Analysts rate Anixa Biosciences Inc a strong buy (4 buy, 0 hold, 0 sell out of 4) with an average price target of $9.67.

Shareholding

Insiders

5.67%

Institutions

14.04%

Largest institutional holders

Fund	Stake
Vanguard Capital Management, LLC	3.83%
UBS Group AG	1.68%
Laird Norton Tyee Trust Co	1.66%
Davidson D A & Co	1.55%
Geode Capital Management, LLC	1.03%
Marshall Wace Asset Management Ltd	0.94%
BlackRock Inc	0.57%
Vanguard Fiduciary Trust Co	0.55%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Anixa Biosciences Inc — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-11-07.